Search Within

Michael Morris

Formats
  1. Meeting Abstract (273)
  2. Journal Article (266)
  3. Review (19)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (580)
  2. Genitourinary Oncology Service (580)
  3. Solid Tumor Oncology Division (580)
  4. Radiology, Department of (163)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (140)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (21)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (238)
  2. Journal of Nuclear Medicine (43)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (248)
  2. American Association for Cancer Research (43)
  3. Society of Nuclear Medicine (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (39)
  6. Elsevier Inc. (27)

More Publishers

Results (580)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Validation and clinical utility of prostate cancer biomarkers
    Journal Article

    Scher, H. I.; Morris, M. J.; Larson, S.; Heller, G.
    Nature Reviews Clinical Oncology (2013)

    Fulltext@MSK | Save
  • The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401)
    Meeting Abstract

    Small, E. J.; Halabi, S.; Carducci, M. A.; Ryan, C. J.; George, D. J.; Mahoney, J. F.; Stadler, W. M.; Morris, M. J.; Kantoff, P.; Monk, J. P.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases
    Meeting Abstract

    Morris, M. J.; Hammers, H. J.; Sweeney, C.; Bloma, M.; Aksnes, A. K.; O'Bryan-Tear, C. G.; Carrasquillo, J. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Morris, M. J.; Bruce, J. Y.; Reyno, L. M.; Anand, B.; Hartford, A.; Jelaca-Maxwell, K.; Lackey, J.; Eisenberger, M. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
    Meeting Abstract

    Kelly, W. K.; Halabi, S.; Carducci, M. A.; George, D. J.; Mahoney, J. F.; Stadler, W. M.; Morris, M. J.; Kantoff, P. W.; Monk, J. P.; Small, E. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Jia, X.; Heller, G.; Schoder, H.; Humm, J.; Haupt, E. C.; Schneider, C.; Scher, H. I.; Larson, S. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy
    Meeting Abstract

    Harzstark, A. L.; Halabi, S.; Kelly, W. K.; Morris, M. J.; Febbo, P. G.; Small, E. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Comparison of PSA, FDG-PET, and Prostate Cancer Working Group 2 (PCWG2) criteria to interpret apparent progression on first post-treatment bone scan
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Haupt, E. C.; Schoder, H.; Scher, H. I.; Larson, S. M.; Morris, M. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save